VTYX Stock Overview
A clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Ventyx Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.06 |
| 52 Week High | US$11.48 |
| 52 Week Low | US$1.67 |
| Beta | 0.37 |
| 11 Month Change | -5.50% |
| 3 Month Change | -6.58% |
| 1 Year Change | -12.71% |
| 33 Year Change | -89.87% |
| 5 Year Change | n/a |
| Change since IPO | -90.20% |
Recent News & Updates
We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully
Nov 14
Ventyx Biosciences: Ready To Escape "The Crash Cycle"
Nov 04Recent updates
We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully
Nov 14Ventyx Biosciences: Ready To Escape "The Crash Cycle"
Nov 04Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?
Jul 12Ventyx Biosciences: Slim Chances In A Fat Market (Rating Downgrade)
Jul 01Ventyx Pivots To Obesity Amid Transformation
Mar 12Here's Why We're Watching Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Situation
Feb 15Ventyx: Too Risky Right Now After Some Poor Data
Jan 18Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth
Sep 21Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate
Feb 20Ventyx Biosciences: Not Chasing This Rally
Sep 18We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth
Aug 19Ventyx Biosciences GAAP EPS of -$0.39 beats by $0.06
Aug 15Ventyx Biosciences autoimmune/autoinflammatory candidate meets phase 1 goals
Jun 29We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate
May 06We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth
Jan 21Shareholder Returns
| VTYX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 16.4% | 2.8% | 2.2% |
| 1Y | -12.7% | 11.8% | 32.6% |
Return vs Industry: VTYX underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: VTYX underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| VTYX volatility | |
|---|---|
| VTYX Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VTYX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VTYX's weekly volatility has decreased from 18% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 75 | Raju Mohan | ventyxbio.com |
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.
Ventyx Biosciences, Inc. Fundamentals Summary
| VTYX fundamental statistics | |
|---|---|
| Market cap | US$130.81m |
| Earnings (TTM) | -US$152.52m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs VTYX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VTYX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$152.52m |
| Earnings | -US$152.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.16 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VTYX perform over the long term?
See historical performance and comparison